Cargando…

P1402: INFUSION OF 14 DAYS BLINATUNOMAB IN COMBINATION WITH CHEMOTHERAPY FOR 46-DAY MRD+ PEDIATRIC B-ALL PATIENTS IN INTERMEDIATE/HIGH-RISK GROUP RESULTS IN MRD CONVERSION.

Detalles Bibliográficos
Autores principales:	Xue, Changwen, Wu, Chao, Yang, Wenyu, Zou, Yao, Guo, Ye, Chen, Yumei, Chen, Xiaojuan, Zhu, Xiaofan, Zhang, LI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430560/ http://dx.doi.org/10.1097/01.HS9.0000972496.76796.17

Ejemplares similares

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)
por: Nagafuji, Koji, et al.
Publicado: (2013)

Mutations in cell elongation genes mreB, mrdA and mrdB suppress the shape defect of RodZ-deficient cells
por: Shiomi, Daisuke, et al.
Publicado: (2013)

MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017)

SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
por: Turcas, Cristina, et al.
Publicado: (2020)

NP-MRD: the Natural Products Magnetic Resonance Database
por: Wishart, David S, et al.
Publicado: (2021)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
por: Askeland, F. B., et al.
Publicado: (2022)

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML
por: Teich, Katrin, et al.
Publicado: (2023)

An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL
por: Greenwood, Matthew, et al.
Publicado: (2021)

Mandibular Repositioning Device (MRD) and Obstructive Sleep Apnea Syndrome
por: Nicolaou, Zoe
Publicado: (2019)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
por: Coffey, David G., et al.
Publicado: (2023)

SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement
por: Szostakowska, Małgorzata, et al.
Publicado: (2018)

Next-generation sequencing–based MRD in adults with ALL undergoing hematopoietic cell transplantation
por: Liang, Emily C., et al.
Publicado: (2023)

A Cost Impact Analysis of clonoSEQ(®) as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany
por: Walzer, Stefan, et al.
Publicado: (2021)

Role of peripheral blood MRD and 18F-FDG PET in the post-CAR relapse setting: a case study of discordant peripheral blood and bone marrow MRD
por: Schultz, Liora, et al.
Publicado: (2023)

Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year
por: van der Linde, Riana, et al.
Publicado: (2023)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML
por: Georgi, Julia-Annabell, et al.
Publicado: (2022)

The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice
por: Turner, Rose, et al.
Publicado: (2022)

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
por: Guolo, Fabio, et al.
Publicado: (2022)

Utility of flow cytometry screening before MRD testing in multiple myeloma
por: Panakkal, Vandana, et al.
Publicado: (2023)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

Highly sensitive MRD tests for ALL based on the IKZF1 Δ3–6 microdeletion
por: Venn, N C, et al.
Publicado: (2012)

Evaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease)
por: Kazemian, Amirhossein, et al.
Publicado: (2021)

NK-cell trogocytosis of CD19 antigen: a rare B-ALL MRD mimicker
por: Panda, Devasis, et al.
Publicado: (2022)

P384: LOW CD19-MFI IN BALL CELLS BEFORE CAR T INFUSION PREDICTED A GOOD RESPONSE AND LONGER MRD-NEGATIVE MAINTENANCE TIME
por: Wang, Ping, et al.
Publicado: (2023)

Comparison of microRNA expression in hippocampus and the marginal division (MrD) of the neostriatum in rats
por: Shu, Si Yun, et al.
Publicado: (2013)

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
por: Kriegsmann, Katharina, et al.
Publicado: (2020)

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
por: Cumbo, Cosimo, et al.
Publicado: (2020)

MRD Tailored Therapy in AML: What We Have Learned So Far
por: Ngai, Lok Lam, et al.
Publicado: (2021)

Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity
por: Suzuki, Kazuhito, et al.
Publicado: (2021)

MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?
por: Pessach, Ilias, et al.
Publicado: (2022)

Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
por: Meddi, Elisa, et al.
Publicado: (2023)

Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
por: Bansal, Radhika, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_geqrjq5vo9fq1iamirqjd06d9n